The future of medicine is increasingly biological, personalised, and precise. Across fields such as cell and gene therapy, protein and nucleic acid drugs, and genomic medicine, companies are developing targeted, often curative treatments that redefine what’s possible in healthcare. At HGF, we work alongside these innovators to build robust IP strategies that protect cutting-edge technology and support commercial success in a competitive, highly regulated environment.c bv

Our Biotherapeutics team brings together deep experience across interrelated but technically distinct specialisms, including gene editing, personalised medicine, antibody and biologic therapeutics, nucleic acid therapeutics and advanced cell and gene therapies. We understand the legal and scientific nuances of each specialism, from evolving case law around diagnostics to the challenges of patenting functionally defined antibodies or CRISPR-based technologies.

The regulatory and IP landscapes in these sectors are constantly changing, with differences between EPO and USPTO approaches to novelty, written description and patentable subject-matter significantly affecting how claims are drafted, prosecuted, and enforced. Our attorneys work globally and collaboratively to ensure our clients’ portfolios reflect both the latest developments and long-term strategic goals.

Whether supporting spin-outs, universities, biotech, or multinational pharmaceutical companies, we combine legal accuracy with first-hand knowledge of R&D pipelines, due diligence, and licensing in this space.